A. de Gramont

发表

The many phases of anaphase.

O. Cohen-Fix, A. de Gramont, 2005, Trends in biochemical sciences.

Targeting the TGFβ pathway for cancer therapy.

Jérôme Cros, E. Raymond, S. Faivre, 2015, Pharmacology & therapeutics.

Novel TGF-β inhibitors ready for prime time in onco-immunology

E. Raymond, S. Faivre, A. de Gramont, 2016, Oncoimmunology.

Adjuvant therapies in advanced hepatocellular carcinoma: moving forward from the STORM

S. Faivre, A. de Gramont, O. Soubrane, 2016, Trials.

Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients

V. Paradis, E. Raymond, S. Faivre, 2015, Oncotarget.

Accomplishments in 2008 in the adjuvant treatment of colon cancer.

J. Marshall, C. Köhne, A. de Gramont, 2009, Gastrointestinal cancer research : GCR.

Efficacy of a sequential treatment strategy with GEMOX-based followed by FOLFIRI-based chemotherapy in advanced biliary tract cancers

E. Raymond, S. Faivre, C. Dreyer, 2016, Acta oncologica.

Prognostic value of c-MET in head and neck cancer: A systematic review and meta-analysis of aggregate data.

E. Raymond, S. Faivre, A. de Gramont, 2017, Oral oncology.

OTX008, a selective small-molecule inhibitor of galectin-1, downregulates cancer cell proliferation, invasion and tumour angiogenesis.

I. Bièche, G. Rabinovich, E. Raymond, 2014, European journal of cancer.

Predictive Factors of Sensitivity to Elisidepsin, a Novel Kahalalide F-Derived Marine Compound

I. Bièche, E. Raymond, C. Galmarini, 2013, Marine drugs.

Targeting the Tumor Microenvironment through mTOR Inhibition and Chemotherapy as Induction Therapy for Locally Advanced Head and Neck Squamous Cell Carcinoma: The CAPRA Study

E. Raymond, S. Faivre, C. Dreyer, 2022, Cancers.

Benzofuran derivatives as anticancer inhibitors of mTOR signaling.

E. Raymond, S. Faivre, M. Serova, 2014, European journal of medicinal chemistry.

Cancer wars: natural products strike back

Qian Zhao, E. Raymond, S. Faivre, 2014, Front. Chem..

Everolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinib

I. Bièche, E. Raymond, S. Faivre, 2016, Oncotarget.

Effects of preset sequential administrations of sunitinib and everolimus on tumour differentiation in Caki-1 renal cell carcinoma

E. Raymond, S. Faivre, M. Serova, 2014, British Journal of Cancer.

Prognostic value of the chemokine receptor CXCR4 and epithelial-to-mesenchymal transition in patients with squamous cell carcinoma of the mobile tongue.

E. Raymond, S. Faivre, S. Albert, 2012, Oral oncology.

Benzofuran derivatives as a novel class of inhibitors of mTOR signaling.

E. Raymond, S. Faivre, M. Serova, 2014, European journal of medicinal chemistry.

Understanding c-MET signalling in squamous cell carcinoma of the head & neck.

E. Raymond, S. Faivre, S. Albert, 2017, Critical reviews in oncology/hematology.

ASAP3 Is a Focal Adhesion-associated Arf GAP That Functions in Cell Migration and Invasion*

Y. Ward, W. Vass, H. Inoue, 2008, Journal of Biological Chemistry.

Perspectives of TGF-β inhibition in pancreatic and hepatocellular carcinomas

E. Raymond, S. Faivre, A. de Gramont, 2013, Oncotarget.

Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.

C. Tournigand, W. Scheithauer, T. Hickish, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Spindle Midzone Microtubule-Associated Proteins Ase1p and Cin8p Affect the Number and Orientation of Astral Microtubules in Saccharomyces cerevisiae

O. Cohen-Fix, A. de Gramont, K. Ross, 2007, Cell cycle.

Targeting cancer cell metabolism in pancreatic adenocarcinoma

E. Raymond, S. Faivre, A. de Gramont, 2015, Oncotarget.

STRATEGIC-1: A multiple-lines, randomized, open-label GERCOR phase III study in patients with unresectable wild-type RAS metastatic colorectal cancer

C. Tournigand, P. Laurent-Puig, F. Bonnetain, 2015, BMC Cancer.

The evolution of adjuvant therapy in the treatment of early-stage colon cancer.

C. Tournigand, A. de Gramont, A. Larsen, 2011, Clinical colorectal cancer.

From chemotherapy to targeted therapy in adjuvant treatment for stage III colon cancer.

C. Tournigand, A. de Gramont, A. Larsen, 2011, Seminars in oncology.

Prohibitin (PHB) expression is associated with aggressiveness in DLBCL and flavagline-mediated inhibition of cytoplasmic PHB functions induces anti-tumor effects

E. Raymond, B. Petit, A. de Gramont, 2019, Journal of experimental & clinical cancer research : CR.

Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.

C. Tournigand, W. Scheithauer, T. Hickish, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ASAP3 Is a Focal Adhesion-associated Arf GAP That Functions in Cell Migration and Invasion*

Y. Ward, W. Vass, H. Inoue, 2008, Journal of Biological Chemistry.

Prohibitin (PHB) expression is associated with aggressiveness in DLBCL and flavagline-mediated inhibition of cytoplasmic PHB functions induces anti-tumor effects

E. Raymond, B. Petit, A. de Gramont, 2019, Journal of Experimental & Clinical Cancer Research.